Stability testing
This article was originally published in The Tan Sheet
Executive Summary
Comment period extended to Dec. 8 for FDA draft guidance on "Stability Testing of Drug Substances and Drug Products," according to an Aug. 24 Federal Register notice. The former deadline was Sept. 9, but the draft is "long and complex and introduces a number of new issues," justifying a longer period for public comment, FDA says. The guidance offers recommendations concerning stability studies conducted to support NDAs, ANDAs, INDs, BLAs, PLAs and supplements ("The Tan Sheet" June 22, p. 21)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning